

# Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2030

<https://marketpublishers.com/r/H85784F6195EN.html>

Date: September 2024

Pages: 291

Price: US\$ 4,950.00 (Single User License)

ID: H85784F6195EN

## Abstracts

The Human Microbiome market is expected to reach USD 4,206.0 million in 2030 from USD 814.6 million in 2024, at a CAGR of 31.5% during the forecast period.

Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the Human Microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.

“The probiotics segment accounted for the largest share by product segment in the human microbiome market in 2023.”

The market is analyzed across four key products: drugs, probiotics, prebiotics, and synbiotics. The segment with the biggest share in the Human Microbiome market in 2023 is Probiotics, Driven by increasing consumer awareness about the benefits of probiotics for gut health, immunity, and overall wellness. Still, the Prebiotics segment held the second-largest market share. Additionally, widespread consumer demand and acceptance as health supplements along with active research supporting health claims on probiotics supports the segment growth. The market is also propelled by the growing popularity of functional foods and beverages containing probiotics.

“The Asia Pacific region is growing at the highest CAGR in the human microbiome market from 2024 to 2030.”

The Asia Pacific is estimated to be the fastest-growing segment of the market primarily due to the increasing awareness of microbiome health, emerging healthcare and biotechnology industries, government support, and funding potential for personalized medicine. The development of high – throughput sequencing technologies has made it possible to sequence the entire microbiome in a single sample, enabling researchers to more accurately and comprehensively characterize the microbial communities that are present in samples. Challenges in terms of data protection and privacy, as well as high cost of human microbiomes, are expected to restrain the growth of the Asia- pacific market. In addition, there may be cultural and linguistic barriers to adoption in certain region, as well as concerns about the accuracy and clinical utility of microbiome sequencing data.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Executives - 25%, CXOs - 30%, and Managers - 45%

By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa -5%..

List of Companies Profiled in the Report:

Nestle S.A. (Switzerland)

Ferring Pharmaceuticals (Switzerland)

BiomeBank (Australia)

Seed Health, Inc. (US)

International Flavors & Fragrances Inc (US)

Pendulum (US)

BioHM Health Inc. (US)

Actial Farmaceutica SRL (Italy)

Optibiotix Health plc (UK)

Resbiotic (US)

Infinant Health Inc (US)

Biogaia AB (Sweden)

Exegi Pharma Llc (US)

#### Research Coverage:

This research report categorizes the Human Microbiome market by Product (Drugs, Probiotics, Prebiotics, and others), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Type (Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT), Peptides, Live Biotherapeutic Products, and Others) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the Human Microbiome market ecosystem is covered in this report.

#### Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Human Microbiome market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's

pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Start-Ups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.

**Product Development/Innovation:** Detailed insights on newly launched products of the Human Microbiome market

**Market Development:** Comprehensive information about lucrative markets - the report analyses the market across varied regions.

**Market Diversification:** Exhaustive information about new services, untapped geographies, recent developments, and investments in the Human Microbiome market

**Competitive Assessment:** Nestle S.A. (Switzerland), Ferring Pharmaceuticals (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc (US), Pendulum (US), BioHM Health Inc. (US), Actial Farmaceutica SRL (Italy), Optibiotix Health plc (UK), Resbiotic (US), Infant Health Inc (US), Biogaia AB (Sweden), and Exegi Pharma Llc (US) among others in the market.

## Contents

### 1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
  - 1.2.1 INCLUSIONS & EXCLUSIONS
- 1.3 STUDY SCOPE
  - 1.3.1 MARKET SEGMENTATION
- 1.4 YEARS CONSIDERED
- 1.5 CURRENCY
- 1.6 RESEARCH LIMITATIONS
- 1.7 STAKEHOLDERS
- 1.8 SUMMARY OF CHANGES
- 1.9 IMPACT OF AI/GEN AI

### 2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
  - 2.1.1 SECONDARY DATA
  - 2.1.2 PRIMARY DATA
- 2.2 MARKET ESTIMATION METHODOLOGY
  - 2.2.1 MARKET ESTIMATION
    - 2.2.1.1 Insights of primary experts
  - 2.2.2 SEGMENTAL MARKET SIZE ESTIMATIONS
- 2.3 MARKET GROWTH RATE PROJECTIONS
- 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 LIMITATIONS
- 2.7 RISK ANALYSIS

### 3 EXECUTIVE SUMMARY

### 4 PREMIUM INSIGHTS

- 4.1 HUMAN MICROBIOME MARKET OVERVIEW
- 4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT AND COUNTRY (2023)
- 4.3 HUMAN MICROBIOME MARKET, BY TYPE (2023 VS. 2030)

## **5 MARKET OVERVIEW**

### **5.1 INTRODUCTION**

### **5.2 MARKET DYNAMICS**

#### **5.2.1 DRIVERS**

5.2.1.1 Collaborative initiatives between organizations and academia in microbiome industry

5.2.1.2 Increasing number of start-ups/SMEs exploring microbiome niche

5.2.1.3 Advancements in microbiome sequencing

#### **5.2.2 RESTRAINTS**

5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes

5.2.2.2 High investments in commercialization of microbiome drugs

#### **5.2.3 OPPORTUNITIES**

5.2.3.1 Increasing demand for personalized medicine

5.2.3.2 Emergence of postbiotics

#### **5.2.4 CHALLENGES**

5.2.4.1 Slow patient adoption of microbiome-based therapies

5.2.4.2 Complexities involved in development of microbiome therapies

### **5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES**

### **5.4 PRICING ANALYSIS**

5.4.1 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY KEY PLAYER

5.4.2 AVERAGE COST RANGE OF HUMAN MICROBIOME PRODUCTS, 2021–2023

5.4.3 AVERAGE SELLING PRICE ANALYSIS, BY REGION

### **5.5 PIPELINE ANALYSIS**

### **5.6 PATENT ANALYSIS**

### **5.7 ECOSYSTEM ANALYSIS**

### **5.8 SUPPLY CHAIN ANALYSIS**

### **5.9 VALUE CHAIN ANALYSIS**

### **5.10 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET**

### **5.11 TECHNOLOGY ANALYSIS**

#### **5.11.1 KEY TECHNOLOGIES**

5.11.1.1 Whole-genome sequencing

5.11.1.2 16s RNA sequencing method

5.11.1.3 Nanopore sequencing

#### **5.11.2 COMPLEMENTARY TECHNOLOGIES**

5.11.2.1 Metatranscriptomics

5.11.2.2 Metagenomics

5.11.2.3 Metabolomics

5.11.3 ADJACENT TECHNOLOGIES

5.11.3.1 Sample preparation

5.11.3.2 Data analysis

5.11.3.3 Library synthesis

5.12 KEY CONFERENCES & EVENTS IN 2024–2025

5.13 REGULATORY ANALYSIS

5.13.1 REGULATORY LANDSCAPE

5.13.1.1 North America

5.13.1.2 Europe

5.13.1.3 Asia Pacific

5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES,  
AND OTHER ORGANIZATIONS

5.14 PORTER'S FIVE FORCES ANALYSIS

5.14.1 THREAT OF NEW ENTRANTS

5.14.2 THREAT OF SUBSTITUTES

5.14.3 BARGAINING POWER OF BUYERS

5.14.4 BARGAINING POWER OF SUPPLIERS

5.14.5 INTENSITY OF COMPETITIVE RIVALRY

5.15 KEY STAKEHOLDERS & BUYING CRITERIA

5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS

5.15.2 BUYING CRITERIA

5.16 CASE STUDY ANALYSIS

5.16.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH  
RECURRENT CLOSTRIDIODES DIFFICILE INFECTION

5.16.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIODES DIFFICILE  
INFECTION

5.16.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3  
PROBIOTIC IN POST-COVID-19 PATIENTS.

5.17 INVESTMENT & FUNDING SCENARIO

5.17.1 OTHER INVESTMENTS AND FUNDING

## **6 HUMAN MICROBIOME MARKET, BY PRODUCT**

6.1 INTRODUCTION

6.2 DRUGS

6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE  
CLINICAL TRIALS TO DRIVE MARKET

## 6.3 PROBIOTICS

6.3.1 GROWING CONSUMER AWARENESS ABOUT PROBIOTICS FOR IMPROVED GUT HEALTH AND IMMUNITY TO AID MARKET GROWTH

## 6.4 PREBIOTICS

6.4.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH

## 6.5 SYNBIOTICS

6.5.1 GROWING DEMAND FOR PERSONALIZED TREATMENT AND RISING INCIDENCE OF DYSBIOSIS TO AUGMENT MARKET GROWTH

# 7 HUMAN MICROBIOME MARKET, BY DISEASE

## 7.1 INTRODUCTION

## 7.2 INFECTIOUS DISEASES

7.2.1 EMERGENCE OF MULTI-DRUG-RESISTANT BACTERIA TO BOOST MARKET GROWTH

## 7.3 GASTROINTESTINAL DISEASES

7.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO PROPEL MARKET GROWTH

## 7.4 ENDOCRINE & METABOLIC DISORDERS

7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET GROWTH

## 7.5 OTHER DISEASES

# 8 HUMAN MICROBIOME MARKET, BY TYPE

## 8.1 INTRODUCTION

## 8.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)

8.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH

## 8.3 LIVE BIOTHERAPEUTIC PRODUCTS (LBP)

8.3.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET

## 8.4 OTHER MICROBIOME TYPES

# 9 HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION

## 9.1 INTRODUCTION

## 9.2 ORAL ROUTE OF ADMINISTRATION

9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO DRIVE MARKET GROWTH

## 9.3 RECTAL ROUTE OF ADMINISTRATION

9.3.1 PRODUCT APPROVALS AND EFFICACY IN TARGETED DELIVERY TO SUPPORT MARKET GROWTH

# 10 HUMAN MICROBIOME MARKET, BY END USER

## 10.1 INTRODUCTION

### 10.2 HOSPITALS & CLINICS

10.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH

### 10.3 LONG-TERM CARE FACILITIES

10.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET

### 10.4 OTHER END USERS

# 11 HUMAN MICROBIOME MARKET, BY REGION

## 11.1 INTRODUCTION

### 11.2 NORTH AMERICA

11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

#### 11.2.2 US

11.2.2.1 Strong ecosystem backed by regulation, research, and funding to drive market

#### 11.2.3 CANADA

11.2.3.1 Government initiatives, independent organizations, and academia collaborations to boost microbiome research

### 11.3 EUROPE

11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

#### 11.3.2 GERMANY

11.3.2.1 Rapid increase in government and private funding to propel market

#### 11.3.3 UK

11.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth

#### 11.3.4 FRANCE

11.3.4.1 Growing awareness and rise of specialized organizations to boost growth

### 11.3.5 ITALY

11.3.5.1 Government intervention and academic institutions  
to drive market growth

### 11.3.6 SPAIN

11.3.6.1 Growing academic research initiatives to boost growth

### 11.3.7 REST OF EUROPE

## 11.4 ASIA PACIFIC

### 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

### 11.4.2 CHINA

11.4.2.1 Increasing R&D investments to drive growth

### 11.4.3 JAPAN

11.4.3.1 Growing geriatric population to present opportunities  
for market growth

### 11.4.4 INDIA

11.4.4.1 Increasing prevalence of chronic diseases to support growth

### 11.4.5 SOUTH KOREA

11.4.5.1 Increasing prevalence of chronic diseases to support growth

### 11.4.6 AUSTRALIA

11.4.6.1 Growing number of product approvals to boost growth

### 11.4.7 REST OF ASIA PACIFIC

## 11.5 LATIN AMERICA

### 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

### 11.5.2 BRAZIL

11.5.2.1 Rising probiotics demand to drive market

### 11.5.3 REST OF LATIN AMERICA

## 11.6 MIDDLE EAST

### 11.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST

### 11.6.2 GCC COUNTRIES

#### 11.6.2.1 Saudi Arabia

11.6.2.1.1 Increasing focus on R&D to boost market growth

#### 11.6.2.2 UAE

11.6.2.2.1 Increasing focus on R&D and healthcare spending to boost market  
growth

#### 11.6.2.3 Rest of GCC countries

### 11.6.3 REST OF MIDDLE EAST

## 11.7 AFRICA

### 11.7.1 STUDIES AND INITIATIVES TO BOOST MARKET GROWTH

### 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

## **12 COMPETITIVE LANDSCAPE**

### **12.1 INTRODUCTION**

#### **12.1.1 KEY PLAYER STRATEGY/RIGHT TO WIN**

#### **12.1.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET**

### **12.2 REVENUE ANALYSIS, 2021–2023**

### **12.3 MARKET SHARE ANALYSIS, 2023**

### **12.4 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023**

#### **12.4.1 STARS**

#### **12.4.2 EMERGING LEADERS**

#### **12.4.3 PERVASIVE PLAYERS**

#### **12.4.4 PARTICIPANTS**

#### **12.4.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023**

##### **12.4.5.1 Company footprint**

##### **12.4.5.2 Product footprint**

##### **12.4.5.3 Type footprint**

##### **12.4.5.4 Disease footprint**

##### **12.4.5.5 Region footprint**

### **12.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023**

#### **12.5.1 PROGRESSIVE COMPANIES**

#### **12.5.2 RESPONSIVE COMPANIES**

#### **12.5.3 DYNAMIC COMPANIES**

#### **12.5.4 STARTING BLOCKS**

#### **12.5.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023**

### **12.6 COMPANY VALUATION & FINANCIAL METRICS**

### **12.7 BRAND/PRODUCT COMPARISON**

### **12.8 COMPETITIVE SCENARIO**

#### **12.8.1 PRODUCT APPROVALS**

#### **12.8.2 DEALS**

## **13 COMPANY PROFILES**

### **13.1 KEY PLAYERS**

#### **13.1.1 INTERNATIONAL FLAVORS & FRAGRANCES, INC.**

##### **13.1.1.1 Business overview**

##### **13.1.1.2 Products offered**

##### **13.1.1.3 Recent developments**

##### **13.1.1.3.1 Deals**

- 13.1.1.4 MnM view
  - 13.1.1.4.1 Key strengths
  - 13.1.1.4.2 Strategic choices
  - 13.1.1.4.3 Weaknesses & competitive threats
- 13.1.2 SEED HEALTH, INC.
  - 13.1.2.1 Business overview
  - 13.1.2.2 Products offered
  - 13.1.2.3 Recent developments
    - 13.1.2.3.1 Deals
  - 13.1.2.4 MnM view
    - 13.1.2.4.1 Key strengths
    - 13.1.2.4.2 Strategic choices
    - 13.1.2.4.3 Weaknesses & competitive threats
- 13.1.3 PENDULUM
  - 13.1.3.1 Business overview
  - 13.1.3.2 Products offered
  - 13.1.3.3 Recent developments
    - 13.1.3.3.1 Deals
  - 13.1.3.4 MnM view
    - 13.1.3.4.1 Key strengths
    - 13.1.3.4.2 Strategic choices
    - 13.1.3.4.3 Weaknesses & competitive threats
- 13.1.4 SERES THERAPEUTICS
  - 13.1.4.1 Business overview
  - 13.1.4.2 Products offered
  - 13.1.4.3 Recent developments
    - 13.1.4.3.1 Product approvals
    - 13.1.4.3.2 Deals
  - 13.1.4.4 MnM view
    - 13.1.4.4.1 Key strengths
    - 13.1.4.4.2 Strategic choices
    - 13.1.4.4.3 Weaknesses & competitive threats
- 13.1.5 FERRING PHARMACEUTICALS
  - 13.1.5.1 Business overview
  - 13.1.5.2 Products offered
  - 13.1.5.3 Recent developments
    - 13.1.5.3.1 Product approvals
    - 13.1.5.3.2 Deals
  - 13.1.5.4 MnM view

- 13.1.5.4.1 Key strengths
- 13.1.5.4.2 Strategic choices
- 13.1.5.4.3 Weaknesses & competitive threats
- 13.1.6 BIOMEBANK
  - 13.1.6.1 Business overview
  - 13.1.6.2 Products offered
  - 13.1.6.3 Recent developments
    - 13.1.6.3.1 Product approvals
    - 13.1.6.3.2 Expansions
- 13.1.7 BIOHM HEALTH INC.
  - 13.1.7.1 Business overview
  - 13.1.7.2 Products offered
  - 13.1.7.3 Recent developments
    - 13.1.7.3.1 Deals
- 13.1.8 ACTIAL FARMACEUTICA SRL
  - 13.1.8.1 Business overview
  - 13.1.8.2 Products offered
- 13.1.9 OPTIBIOTIX HEALTH PLC
  - 13.1.9.1 Business overview
  - 13.1.9.2 Products offered
  - 13.1.9.3 Recent developments
    - 13.1.9.3.1 Product approvals
    - 13.1.9.3.2 Deals
- 13.1.10 RESBIOTIC
  - 13.1.10.1 Business overview
  - 13.1.10.2 Products offered
  - 13.1.10.3 Recent developments
    - 13.1.10.3.1 Expansions
- 13.1.11 INFINANT HEALTH INC.
  - 13.1.11.1 Business overview
  - 13.1.11.2 Products offered
- 13.1.12 BIOGAIA AB
  - 13.1.12.1 Business overview
  - 13.1.12.2 Products offered
  - 13.1.12.3 Recent developments
    - 13.1.12.3.1 Deals
    - 13.1.12.3.2 Expansions
- 13.1.13 EXEGI PHARMA, LLC
  - 13.1.13.1 Business overview

- 13.1.13.2 Products offered
- 13.1.13.3 Recent developments
  - 13.1.13.3.1 Deals

## 13.2 OTHER PLAYERS

- 13.2.1 AOBIOME
- 13.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
- 13.2.3 NUBIYOTA
- 13.2.4 OXThera AB
- 13.2.5 NEXBIOME
- 13.2.6 VEDANTA BIOSCIENCES, INC.
- 13.2.7 ENTEROME
- 13.2.8 APSEN FARMAC?UTICA S.A.
- 13.2.9 METAGEN THERAPEUTICS, INC.
- 13.2.10 SNIPR BIOME
- 13.2.11 MAAT PHARMA SA
- 13.2.12 MIKROBIOMIK

## 14 APPENDIX

- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
- TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
- TABLE 2 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS
- TABLE 3 EXAMPLES OF INDUSTRY COLLABORATIONS IN HUMAN MICROBIOME MARKET
- TABLE 4 LIST OF START-UPS/SMES IN HUMAN MICROBIOME MARKET
- TABLE 5 AVERAGE COST RANGE OF HUMAN MICROBIOME PRODUCTS, 2021–2023
- TABLE 6 KEY CONFERENCES & EVENTS IN HUMAN MICROBIOME MARKET (2024–2025)
- TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 11 REGULATORY LANDSCAPE OF LIVE BIOTHERAPEUTIC PRODUCTS

TABLE 12 HUMAN MICROBIOME MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 13 HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)

TABLE 14 MAJOR INVESTMENT AND FUNDING

TABLE 15 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 16 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION,

### **2023–2030 (USD MILLION)**

TABLE 17 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 18 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 19 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 20 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 21 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 22 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 23 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION,

### **2023–2030 (USD MILLION)**

TABLE 24 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 25 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 26 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 27 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 28 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR PREBIOTICS,

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 29 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR PREBIOTICS,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 30 HUMAN MICROBIOME MARKET FOR SYNBIOTICS, BY REGION,

**2023–2030 (USD MILLION)**

TABLE 31 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 32 EUROPE: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 33 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 34 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 35 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 36 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR SYNBIOTICS,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 37 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD  
MILLION)

TABLE 38 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS  
FOR INFECTIOUS DISEASES

TABLE 39 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES,  
BY REGION, 2023–2030 (USD MILLION)

TABLE 40 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR  
GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 41 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL  
DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 42 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR  
GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 43 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR  
GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 44 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR  
GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 45 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR  
GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 46 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC

DISORDERS,

BY REGION, 2023–2030 (USD MILLION)

TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 50 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 51 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 52 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 53 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 54 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 55 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 56 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 57 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 58 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 59 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 60 HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 61 HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY REGION, 2023–2030 (USD MILLION)

TABLE 62 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 63 EUROPE: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 64 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 65 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 66 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 67 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT),

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 68 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP),

BY REGION, 2023–2030 (USD MILLION)

TABLE 69 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 70 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 71 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 72 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 73 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 74 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS (LBP), BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 75 OTHER MICROBIOME TYPES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 76 NORTH AMERICA: OTHER MICROBIOME TYPES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 77 EUROPE: OTHER MICROBIOME TYPES MARKET,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 78 ASIA PACIFIC: OTHER MICROBIOME TYPES MARKET,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 79 LATIN AMERICA: OTHER MICROBIOME TYPES MARKET,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 80 MIDDLE EAST: OTHER MICROBIOME TYPES MARKET,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 81 GCC COUNTRIES: OTHER MICROBIOME TYPES MARKET,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 82 HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,

### **2023–2030 (USD MILLION)**

TABLE 83 HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF  
ADMINISTRATION,  
BY REGION, 2023–2030 (USD MILLION)

TABLE 84 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ORAL ROUTE  
OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 85 EUROPE: HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF  
ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 86 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF  
ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 87 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF  
ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 88 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ORAL ROUTE OF  
ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 89 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ORAL ROUTE  
OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 90 HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF  
ADMINISTRATION,  
BY REGION, 2023–2030 (USD MILLION)

TABLE 91 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR RECTAL  
ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 92 EUROPE: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF  
ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 93 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF  
ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 94 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE

OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 95 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 96 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 97 HUMAN MICROBIOME MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 98 HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 102 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 103 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 104 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 105 HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 106 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 107 EUROPE: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 109 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 110 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 111 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 112 HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 113 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 114 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 115 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 116 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 117 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 118 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 119 HUMAN MICROBIOME MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 120 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 121 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 122 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 123 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 124 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 125 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 126 NORTH AMERICA: MACROECONOMIC INDICATORS

TABLE 127 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 128 US: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD

MILLION)

TABLE 129 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 130 US: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 131 US: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 132 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT,

**2023–2030 (USD MILLION)**

TABLE 133 CANADA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 134 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 135 CANADA: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 136 CANADA: HUMAN MICROBIOME MARKET, BY END USER,

**2023–2030 (USD MILLION)**

TABLE 137 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY,

**2023–2030 (USD MILLION)**

TABLE 138 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT,

**2023–2030 (USD MILLION)**

TABLE 139 EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 140 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 141 EUROPE: HUMAN MICROBIOME MARKET, BY ROUTE OF

ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 142 EUROPE: HUMAN MICROBIOME MARKET, BY END USER,

**2023–2030 (USD MILLION)**

TABLE 143 EUROPE: MACROECONOMIC INDICATORS

TABLE 144 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT,

**2023–2030 (USD MILLION)**

TABLE 145 GERMANY: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 146 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE,

**2023–2030 (USD MILLION)**

TABLE 147 GERMANY: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 148 GERMANY: HUMAN MICROBIOME MARKET, BY END USER,

**2023–2030 (USD MILLION)**

TABLE 149 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 150 UK: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 151 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 152 UK: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 153 UK: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 154 HUMAN MICROBIOME STARTUPS IN FRANCE

TABLE 155 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT,

**2023–2030 (USD MILLION)**

TABLE 156 FRANCE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 157 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 158 FRANCE: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 159 FRANCE: HUMAN MICROBIOME MARKET, BY END USER,

**2023–2030 (USD MILLION)**

TABLE 160 ITALY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 161 ITALY: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 162 ITALY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 163 ITALY: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 164 ITALY: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 165 SPAIN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 166 SPAIN: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 167 SPAIN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 168 SPAIN: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 169 SPAIN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030  
(USD MILLION)

TABLE 170 REST OF EUROPE: HUMAN MICROBIOME MARKET,  
BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 171 REST OF EUROPE: HUMAN MICROBIOME MARKET,  
BY TYPE, 2023–2030 (USD MILLION)

TABLE 172 REST OF EUROPE: HUMAN MICROBIOME MARKET,  
BY DISEASE, 2023–2030 (USD MILLION)

TABLE 173 REST OF EUROPE: HUMAN MICROBIOME MARKET,  
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 174 REST OF EUROPE: HUMAN MICROBIOME MARKET,  
BY END USER, 2023–2030 (USD MILLION)

TABLE 175 ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 176 ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 177 ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY TYPE, 2023–2030 (USD MILLION)

TABLE 178 ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY DISEASE, 2023–2030 (USD MILLION)

TABLE 179 ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 180 ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY END USER, 2023–2030 (USD MILLION)

TABLE 181 ASIA PACIFIC: MACROECONOMIC INDICATORS

TABLE 182 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030  
(USD MILLION)

TABLE 183 CHINA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD  
MILLION)

TABLE 184 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD  
MILLION)

TABLE 185 CHINA: HUMAN MICROBIOME MARKET, BY ROUTE OF  
ADMINISTRATION,

### **2023–2030 (USD MILLION)**

TABLE 186 CHINA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030  
(USD MILLION)

TABLE 187 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030  
(USD MILLION)

TABLE 188 JAPAN: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD  
MILLION)

TABLE 189 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD  
MILLION)

TABLE 190 JAPAN: HUMAN MICROBIOME MARKET, BY ROUTE OF  
ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 191 JAPAN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030  
(USD MILLION)

TABLE 192 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD  
MILLION)

TABLE 193 INDIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD  
MILLION)

TABLE 194 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD  
MILLION)

TABLE 195 INDIA: HUMAN MICROBIOME MARKET, BY ROUTE OF  
ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 196 INDIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030  
(USD MILLION)

TABLE 197 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY PRODUCT,

**2023–2030 (USD MILLION)**

TABLE 198 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY TYPE,

**2023–2030 (USD MILLION)**

TABLE 199 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY DISEASE,

**2023–2030 (USD MILLION)**

TABLE 200 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY ROUTE OF

ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 201 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY END USER,

**2023–2030 (USD MILLION)**

TABLE 202 AUSTRALIA: HUMAN MICROBIOME MARKET, BY PRODUCT,

**2023–2030 (USD MILLION)**

TABLE 203 AUSTRALIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030  
(USD MILLION)

TABLE 204 AUSTRALIA: HUMAN MICROBIOME MARKET, BY DISEASE,

**2023–2030 (USD MILLION)**

TABLE 205 AUSTRALIA: HUMAN MICROBIOME MARKET, BY ROUTE OF  
ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 206 AUSTRALIA: HUMAN MICROBIOME MARKET, BY END USER,

**2023–2030 (USD MILLION)**

TABLE 207 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 208 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY TYPE, 2023–2030 (USD MILLION)

TABLE 209 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY DISEASE, 2023–2030 (USD MILLION)

TABLE 210 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 211 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET,  
BY END USER, 2023–2030 (USD MILLION)

TABLE 212 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY,

**2023–2030 (USD MILLION)**

TABLE 213 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT,

**2023–2030 (USD MILLION)**

TABLE 214 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY TYPE,

**2023–2030 (USD MILLION)**

TABLE 215 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE,

**2023–2030 (USD MILLION)**

TABLE 216 LATIN AMERICA: HUMAN MICROBIOME MARKET,  
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 217 LATIN AMERICA: HUMAN MICROBIOME MARKET,  
BY END USER, 2023–2030 (USD MILLION)

TABLE 218 LATIN AMERICA: MACROECONOMIC INDICATORS

TABLE 219 BRAZIL: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030  
(USD MILLION)

TABLE 220 BRAZIL: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD  
MILLION)

TABLE 221 BRAZIL: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030  
(USD MILLION)

TABLE 222 BRAZIL: HUMAN MICROBIOME MARKET, BY ROUTE OF  
ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 223 BRAZIL: HUMAN MICROBIOME MARKET, BY END USER,

**2023–2030 (USD MILLION)**

TABLE 224 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET,  
BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 225 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET,  
BY TYPE, 2023–2030 (USD MILLION)

TABLE 226 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET,  
BY DISEASE, 2023–2030 (USD MILLION)

TABLE 227 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET,  
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 228 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET,  
BY END USER, 2023–2030 (USD MILLION)

TABLE 229 MIDDLE EAST: HUMAN MICROBIOME MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 230 MIDDLE EAST: HUMAN MICROBIOME MARKET,  
BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 231 MIDDLE EAST: HUMAN MICROBIOME MARKET,  
BY TYPE, 2023–2030 (USD MILLION)

TABLE 232 MIDDLE EAST: HUMAN MICROBIOME MARKET,  
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 233 MIDDLE EAST: HUMAN MICROBIOME MARKET,  
BY DISEASE, 2023–2030 (USD MILLION)

TABLE 234 MIDDLE EAST: HUMAN MICROBIOME MARKET,  
BY END USER, 2023–2030 (USD MILLION)

TABLE 235 MIDDLE EAST: MACROECONOMIC INDICATORS

TABLE 236 GCC COUNTRIES: HUMAN MICROBIOME MARKET,  
BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 237 GCC COUNTRIES: HUMAN MICROBIOME MARKET,  
BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 238 GCC COUNTRIES: HUMAN MICROBIOME MARKET,  
BY TYPE, 2023–2030 (USD MILLION)

TABLE 239 GCC COUNTRIES: HUMAN MICROBIOME MARKET,  
BY DISEASE, 2023–2030 (USD MILLION)

TABLE 240 GCC COUNTRIES: HUMAN MICROBIOME MARKET,  
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 241 GCC COUNTRIES: HUMAN MICROBIOME MARKET,  
BY END USER, 2023–2030 (USD MILLION)

TABLE 242 SAUDI ARABIA: HUMAN MICROBIOME MARKET,  
BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 243 SAUDI ARABIA: HUMAN MICROBIOME MARKET,  
BY TYPE, 2023–2030 (USD MILLION)

TABLE 244 SAUDI ARABIA: HUMAN MICROBIOME MARKET,  
BY DISEASE, 2023–2030 (USD MILLION)

TABLE 245 SAUDI ARABIA: HUMAN MICROBIOME MARKET,  
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 246 SAUDI ARABIA: HUMAN MICROBIOME MARKET,  
BY END USER, 2023–2030 (USD MILLION)

TABLE 247 UAE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD  
MILLION)

TABLE 248 UAE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD  
MILLION)

TABLE 249 UAE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD

MILLION)

TABLE 250 UAE: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION,

**2023–2030 (USD MILLION)**

TABLE 251 UAE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 252 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 253 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 254 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 255 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 256 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 257 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 258 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 259 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 260 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 261 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 262 AFRICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 263 AFRICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 264 AFRICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2030 (USD MILLION)

TABLE 265 AFRICA: HUMAN MICROBIOME MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 266 AFRICA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 267 AFRICA: MACROECONOMIC INDICATORS

TABLE 268 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS  
IN HUMAN MICROBIOME MARKET

TABLE 269 HUMAN MICROBIOME MARKET: DEGREE OF COMPETITION

TABLE 270 HUMAN MICROBIOME MARKET: PRODUCT FOOTPRINT

TABLE 271 HUMAN MICROBIOME MARKET: TYPE FOOTPRINT

TABLE 272 HUMAN MICROBIOME MARKET: DISEASE FOOTPRINT

TABLE 273 HUMAN MICROBIOME MARKET: REGION FOOTPRINT

TABLE 274 HUMAN MICROBIOME MARKET: DETAILED LIST OF KEY  
STARTUPS/SMES

TABLE 275 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF  
KEY START UPS/SMES

TABLE 276 HUMAN MICROBIOME MARKET: PRODUCT APPROVALS,  
JANUARY 2021–AUGUST 2024

TABLE 277 IMMUNOTHERAPY DRUGS MARKET: DEALS, JANUARY 2021–AUGUST  
2024

TABLE 278 INTERNATIONAL FLAVORS & FRAGRANCES, INC.: COMPANY  
OVERVIEW

TABLE 279 INTERNATIONAL FLAVORS & FRAGRANCES, INC.: PRODUCTS  
OFFERED

TABLE 280 INTERNATIONAL FLAVORS & FRAGRANCES, INC.: DEALS,  
JANUARY 2021–MAY 2024

TABLE 281 SEED HEALTH, INC.: COMPANY OVERVIEW

TABLE 282 SEED HEALTH, INC.: PRODUCTS OFFERED

TABLE 283 SEED HEALTH, INC.: DEALS, JANUARY 2021–MAY 2024

TABLE 284 PENDULUM: COMPANY OVERVIEW

TABLE 285 PENDULUM: PRODUCTS OFFERED

TABLE 286 PENDULUM: DEALS, JANUARY 2021–MAY 2024

TABLE 287 SERES THERAPEUTICS: COMPANY OVERVIEW

TABLE 288 SERES THERAPEUTICS: PRODUCTS OFFERED

TABLE 289 SERES THERAPEUTICS: PRODUCT APPROVALS, JANUARY  
2021–MAY 2024

TABLE 290 SERES THERAPEUTICS: DEALS, JANUARY 2021–MAY 2024

TABLE 291 FERRING PHARMACEUTICALS: COMPANY OVERVIEW

TABLE 292 FERRING PHARMACEUTICALS: PRODUCTS OFFERED

TABLE 293 FERRING PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY  
2021–MAY 2024

TABLE 294 FERRING PHARMACEUTICALS: DEALS, JANUARY 2021–MAY 2024

TABLE 295 BIOMEBANK: COMPANY OVERVIEW

TABLE 296 BIOMEBANK: PRODUCTS OFFERED

TABLE 297 BIOMEBANK: PRODUCT APPROVALS, JANUARY 2021–MAY 2024

TABLE 298 BIOMEBANK.: EXPANSIONS, JANUARY 2021–MAY 2024

TABLE 299 BIOHM HEALTH INC.: COMPANY OVERVIEW

TABLE 300 BIOHM HEALTH INC.: PRODUCTS OFFERED

TABLE 301 BIOHM HEALTH INC.: DEALS, JANUARY 2021–MAY 2024

TABLE 302 ACTIAL FARMACEUTICA SRL: COMPANY OVERVIEW

TABLE 303 ACTIAL FARMACEUTICA SRL: PRODUCTS OFFERED

TABLE 304 OPTIBIOTIX HEALTH PLC: COMPANY OVERVIEW

TABLE 305 OPTIBIOTIX HEALTH PLC: PRODUCTS OFFERED

TABLE 306 OPTIBIOTIX HEALTH PLC: PRODUCT APPROVALS, JANUARY 2021–MAY 2024

TABLE 307 OPTIBIOTIX HEALTH PLC: DEALS, JANUARY 2021–MAY 2024

TABLE 308 RESBIOTIC: COMPANY OVERVIEW

TABLE 309 RESBIOTIC: PRODUCTS OFFERED

TABLE 310 RESBIOTIC: EXPANSIONS, JANUARY 2021–MAY 2024

TABLE 311 INFINANT HEALTH INC.: COMPANY OVERVIEW

TABLE 312 INFINANT HEALTH INC.: PRODUCTS OFFERED

TABLE 313 BIOGAIA AB: COMPANY OVERVIEW

TABLE 314 BIOGAIA AB: PRODUCTS OFFERED

TABLE 315 BIOGAIA AB: DEALS, JANUARY 2021–MAY 2024

TABLE 316 BIOGAIA AB: EXPANSIONS, JANUARY 2021–MAY 2024

TABLE 317 EXEGI PHARMA, LLC: COMPANY OVERVIEW

TABLE 318 EXEGI PHARMA, LLC: PRODUCTS OFFERED

TABLE 319 EXEGI PHARMA, LLC: DEALS, JANUARY 2021–MAY 2024

TABLE 320 AOBIOOME: COMPANY OVERVIEW

TABLE 321 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW

TABLE 322 NUBIYOTA: COMPANY OVERVIEW

TABLE 323 OXThera AB: COMPANY OVERVIEW

TABLE 324 NEXBIOME: COMPANY OVERVIEW

TABLE 325 VEDANTA BIOSCIENCES, INC.: COMPANY OVERVIEW

TABLE 326 ENTEROME: COMPANY OVERVIEW

TABLE 327 APSEN FARMAC?UTICA S/A.: COMPANY OVERVIEW

TABLE 328 METAGEN THERAPEUTICS, INC.: COMPANY OVERVIEW

TABLE 329 SNIPR BIOME: COMPANY OVERVIEW

TABLE 330 MAAT PHARMA SA: COMPANY OVERVIEW

TABLE 331 MIKROBIOMIK: COMPANY OVERVIEW

## About

The human microbiome market for diabetes is expected to be active from 2022 onwards with North America estimated to grow at a highest CAGR of XX% from 2022 to 2023. This geographic segment is poised to reach \$XX million by 2023 from \$XX million in 2022.

Several leading players in the human microbiome market for diabetes include Metabionics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Merck (U.S.), and Enterome Bioscience (France).

The therapeutic segment is expected to dominate the human microbiome applications market from 2019 onwards and is expected to grow at a CAGR of XX% from 2019 to 2023, to reach \$XX million by 2023. This segment is estimated to be the fastest-growing segment and is expected to lead the human microbiome application market by 2019. This is mainly attributed to the identification of new and specific bacterial macromolecules as potential therapeutic targets and the need for reliable, precise, and quicker detection of chronic lifestyle diseases and various other disorders.

The diagnostic segment is expected to enter the market in 2021 and estimated to grow at a CAGR of XX% from 2021 to 2023, to reach \$XX million by 2023. However, limited awareness about microbiome-based applications and stringent regulatory policies are restricting the growth of this market.

Probiotics segment is expected to dominate the global human microbiome market in 2019 and estimated to grow at a CAGR of XX% from 2019 to 2023, to reach \$XX million by 2023. The prebiotics segment is expected to be the fastest-growing, projected to grow at a CAGR of XX% from 2019 to reach \$XX million by 2023. Several leading market players are focusing on increasing their market share in the probiotics and prebiotics along with drugs, through various organic and inorganic growth strategies.

## I would like to order

Product name: Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2030

Product link: <https://marketpublishers.com/r/H85784F6195EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H85784F6195EN.html>